FOCUS ISSUE: DRUG-ELUTING STENTS: TAXUS-IV
Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes
Analysis from the TAXUS-IV trial
Jeffrey W. Moses, MD, FACC*, ,
Roxana Mehran, MD, FACC*,,
Eugenia Nikolsky, MD*,,
John M. Lasala, MD, FACC ,1,
Woodrow Corey, MD, FACC ,
Glenn Albin, MD, FACC||,
Cary Hirsch, MD, FACC¶,
Martin B. Leon, MD, FACC*,,
Mary E. Russell, MD, FACC#,2,
Stephen G. Ellis, MD, FACC**,1 and
Gregg W. Stone, MD, FACC*,,1,*
* Columbia University Medical Center, New York, New York
The Cardiovascular Research Foundation, New York, New York
Washington University School of Medicine, St. Louis, Missouri
Community Hospitals of Indianapolis, Indianapolis, Indiana
|| Saint Mary’s Hospital, Duluth, Minnesota
¶ Valley Hospital, Ridgewood, New Jersey
# Boston Scientific Corp., Natick, Massachusetts
** Cleveland Clinic Foundation, Cleveland, Ohio.
Manuscript received June 28, 2004;
revised manuscript received October 18, 2004,
accepted October 25, 2004.
* Reprint requests and correspondence: Dr. Gregg W. Stone, The Cardiovascular Research Foundation, 55 East 59th Street, 6th floor, New York, New York 10022. (Email: gstone{at}crf.org).
OBJECTIVES: We sought to investigate the outcomes of paclitaxel-eluting stent implantation in patients with unstable angina or non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI).
BACKGROUND: Whether the paclitaxel-eluting stent is safe and effective in patients with acute coronary syndromes (ACS) is unknown.
METHODS: In the TAXUS-IV trial, 1,314 patients with stable or unstable ischemic syndromes undergoing PCI were randomized to treatment with either the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scientific Corp., Natick, Massachusetts). The results were stratified by the acuity of the presenting clinical syndrome.
RESULTS: Acute coronary syndromes were present in 450 patients (34.2%), 237 of whom were assigned to paclitaxel-eluting stents and 213 to bare-metal stents. The baseline and procedural characteristics were well matched between the groups. Clinical outcomes at 30 days were similar with both stents. At one-year follow-up, patients with ACS assigned to the paclitaxel-eluting stent compared to the control stent had strikingly lower rates of target lesion revascularization (TLR) (3.9% vs. 16.0%, p < 0.0001) and major adverse cardiac events (11.1 vs. 21.7%, p = 0.002). By multivariate analysis, ACS was an independent predictor of in-stent restenosis in the cohort treated with bare-metal stents (hazard ratio [HR] = 2.03 [95% confidence interval (CI) 1.05 to 3.92], p = 0.035), while among patients randomized to the paclitaxel-eluting stents, ACS was an independent predictor of freedom from restenosis (HR = 0.27 [95% CI 0.08 to 0.97], p = 0.04).
CONCLUSIONS: The use of the paclitaxel-eluting TAXUS stent was safe in patients with unstable ischemic syndromes, and was associated with marked reduction of ischemia-driven TLR and adverse cardiac events at one year.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | CI = confidence interval | | CK = creatine kinase | | HR = hazard ratio | | MACE = major adverse cardiac events | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
S. M. Zimmer, J. Liu, J. L. Clayton, D. S. Stephens, and J. P. Snyder
Paclitaxel Binding to Human and Murine MD-2
J. Biol. Chem.,
October 10, 2008;
283(41):
27916 - 27926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Aradi, A. Konyi, L. Palinkas, T. Berki, T. Pinter, T. Tahin, I. Horvath, L. Papp, and A. Komocsi
Thienopyridine Therapy Influences Late Outcome After Coronary Stent Implantation
Angiology,
May 1, 2008;
59(2):
172 - 178.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Austin, J. P Pell, and K. G Oldroyd
Drug-eluting stents: do the risks really outweigh the benefits?
Heart,
February 1, 2008;
94(2):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ribichini, F. Tomai, L. Paloscia, G. Di Sciascio, G. Carosio, M. Romano, E. Verna, M. Galli, C. Tamburino, N. De Cesare, et al.
Steroid-eluting stents in patients with acute coronary syndrome: the Dexamethasone Eluting Stent Italian REgistry
Heart,
May 1, 2007;
93(5):
598 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, K. Dawkins, C. Macaya, B. de Bruyne, E. Teiger, J. Fajadet, R. Gert, S. De Servi, A. Ramondo, K. Wittebols, et al.
Impact of Stable Versus Unstable Coronary Artery Disease on 1-Year Outcome in Elective Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents: A Subanalysis of the ARTS II Trial
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes and E. M. Antman
Clinical Guidelines and Practice: In Search of the Truth
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1129 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1689 - 1706.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
184 - 202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Nawarskas and L. A. Osborn
Paclitaxel-eluting stents in coronary artery disease
Am. J. Health Syst. Pharm.,
November 1, 2005;
62(21):
2241 - 2251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1206 - 1212.
[Full Text]
[PDF]
|
|
|
|
